The phase II trial DESTINY-PanTumor02 demonstrated that T-DXd exhibited favorable efficacy and safety profiles in various tumor types with HER2 overexpression, including patients with cervical cancer, endometrial cancer, ovarian cancer, biliary tract cancer, and bladder cancer (ORR 37.1%, DCR 83.2%, median duration of response 11.8 months). Here, ERBB2 is linked to cervical cancer.